logo-loader

Scancell targets emerging class of cancer treatment with latest addition to pipeline

Published: 02:50 23 Jun 2022 EDT

Scancell Holdings PLC -

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) is targeting an emerging class of cancer treatment with the latest addition to its pipeline.

The early-stage asset will harness the potential of monoclonal antibodies (MABs) developed using its GlyMab platform, which target sugar sequences, or ‘motifs’.

This, Scancell believes, confers certain advantages over the traditional MABs, which recognise and find certain proteins on cancer cells.

Specifically, the company’s scientists are aiming to develop T-cell bispecific antibodies or TCBs.

Put simply, this new breed of treatment triggers an immune response to cancer by activating killer T-cells and tumour cell death.

To reduce the potential toxic side-effects of the new treatment, specifically the prospect of triggering a cytokine storm within the immune system, Scancell is in-licensing a technology from an Oxford-based company called mAbsolve.

Scancell said it will take its discovery into phase I clinical trials in "due course".

"Over the past year we have been evaluating the optimal products for Scancell to develop through exploiting our Glymab platform,” said chief executive, professor Lindy Durrant.

“We believe we can add considerable value to the antibody portfolio by taking TCB products into the clinic, as opposed to out-licensing them at the preclinical stage.”

In parallel, the company will also use the GlyMab platform to deliver cytotoxic drugs (ADC) or cell therapies (CAR). It said it is looking at potential deals to leverage its technology in this regard.

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 09/19/2023